Infectious Diseases | |
|---|---|
| Study Name | Principal Investigator |
| LBx-2001 – A Two-Part, Phase 2, Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant Escherichia coli (a.k.a. ELIMINATE trial). Read more. |
Suraj Saggar, DO |
| MK-4482-023-00 – A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression. Read more. |
Suraj Saggar, DO |
| C509101 – An Interventional Efficacy and Safety, Phase 3, Randomized, Double-Blind, 3-Arm Study to Investigate Ibuzatrelvir in Adults with Symptomatic COVID-19 Who Are Severely Immunocompromised. Read more. |
Suraj Saggar, DO |
